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ited options or where the cure is sometimes just as deadly 
as the disease, as is the case in chemotherapy and radia-
tion treatments.  With its versatility, ECP becomes an addi-
tional option even for patients already using other thera-
pies.  Trials have produced extremely promising results for 
diseases with little or no hope.  To date, ECP has only been 
approved for treatment in CTCL and GvHD, but current 
trials are expanding its usage.  ECP has promising potential 
to be the cure of the future pertaining to immune system 
related diseases. 
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Introduction 
The Epidermal Growth Factor Receptor (EGFR), also known 
as ErbB1 or Her1 in humans, was first discovered by Stan-
ley Cohen in the 1970’s (Yarden, Sliwkowski, 2001).  Since 
then, our understanding of the protein and its critical role 
in numerous forms of cancer has advanced in enormous 
strides.  Advances in this area have proven to be fruitful, 
and much hope is put into future development for cancer 
cures.  EGFR is now understood to be one of four members 
of the ErbB interactive family of Tyrosine Kinase (TK) Pro-
teins.  EGFR, as well as ErbB 2, 3, and 4 (Her 2, 3, 4) are 
phosphorylation inducing proteins on the Tyrosine portion 
of the receptors (Yarden, Sliwkowski, 2001).  EGFR carries 
out numerous signal transduction pathways which result in 
cellular proliferation, metastasis, and apoptotic aversion, 
all clearly oncogenic activities.  Consequently, EGFR com-
monly causes numerous types of cancers whenever-
expressed in epithelial tissue throughout the body (Heist, 
Christiani, 2009).  In Non Small Cell Lung Cancer (NSCLC) 
specifically, EGFR over expression is the most common 
cause, leading to much research and analysis of this pro-
tein, and its mutations in regard to lung cancer.  Numerous 
drug therapies have been developed to target the specific 
mutations that were found as causes of 
NSCLC.  Understanding of the structure and mechanism of 
this protein is crucial to the development of biomarkers to 
target specific populations containing the mutation to al-
low for further development of target therapy for cancer.   
Methods 
Various databases were utilized to gather papers on re-
search studies and reviews on the subject matter to ana-
lyze it and determine possible biomarker methods and 
their efficiency.  Articles were found in Google Scholar, 
Touro Library Database, and Rutgers University Data-
base.  These papers were analyzed and used to come to 
the conclusions explained in the discussion of this paper. 
Results: 
EGFR 
EGFR is a tri-domain membranous receptor protein con-
sisting of an extracellular ligand-binding domain mainly 
comprised of cysteine, a hydrophobic transmembranous 
area, and an intracellular Tyrosine Kinase Domain (Yarden, 
2001).  The Tyrosine Kinase domain is made up of a jux-
tamembrane region, an area for TK activity, and a C -
terminal domain (Markus, Alain, 2013).  A number of lig-
ands contain an affinity to EGFR including the Transforming 
Growth Factor-α (TGF-α), Epidermal Growth Factor (EGF) 
and Amphiregulin (Figure 1) (Huang, Harari,1999).  All 
EGFR ligands contain around 50 amino acids including six 
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cysteine residues in β-sheet formation and are highly regu-
lated by numerous signal transduction pathways through-
out the cell (Yarden, Sliwkowski, 2001).  TGF-α is the most 
common ligand (Vealel, et. al. 1987).  Following EGFR bind-
ing, dimerization of EGFR occurs to form a homodimer 
with an identical receptor or to form a heterodimer with a 
different protein of the ErbB family (Isobe et. al. 
2005).  Heterodimers are stronger than homodimers with 
a smaller rate of ligand dissociation, increased period of tie 
at the cell surface, and increased mitogenic capabili-
ties.  Dimerization leads to autophosphorylation of Tyro-
sine residues of the cytoplasmic region of the protein it-
self.  The specific regions activated on the Kinase domain, 
and consequently the specific pathways activated, are de-
pendent on the ligand’s identity as well as EGFR’s dimeriza-
tion partner.  EGFR’s activation allows it to bind to cyto-
plasmic messenger proteins which initiate various signal 
transduction cascades resulting in cell proliferation, metas-
tasis, and apoptosis aversion (Yarden, Sliwkowski, 2001). 
Raf-MEK-ERK Mitogen-Activated Protein Kinase  
Cascade 
 The most common EGFR signal transduction path-
way is the Raf-MEK-ERK Mitogen-Activated Protein Kinase 
Cascade (Figure 2).  This cascade contains a set of its own 
mutations throughout the steps of the pathway which are 
leading causes of cancer as well.  Mammalian cascades 
involving Mitogen-Activated Protein Kinases (MAPK’s) are 
part of a three step signaling process.  The MAPK Kinase 
Kinase (MAPKKK) signals the MAP Kinase (MAPKK) which 
then signals the MAPK (Roberts, Der, 2007).  In the EGFR 
MAPK cascade, active EGFR stimulates Raf, the MAPKKK, 
through association with adaptor protein Grb2 which re-
cruits SOS-1 nucleotide exchange factors to the cell mem-
brane.  SOS-1 activates Ras proteins by exchanging the 
GDP bound to Ras for GTP.  The activated Ras recruits Raf 
to the cell membrane and activates it through a complex 
process involving phosphorylation (Friday, Adjei, 
2008).  The Raf MAPKKK phosphorylates and activates MEK 
1 and 2, the MAPKK’s, which phosphorylate the MAPK’s- 
Extracellular signal-regulated kinases (ERK 1 and 
2).  Activated ERK’s go on to regulate numerous proteins 
and transcription factors, resulting in cell proliferation and 
survival.  Although this pathway has previously been con-
sidered linear, in reality it involves many complex interac-
tions with other pathways which regulate the different 
steps, mainly Raf Activation.  Studies have shown that mu-
tations in each step along the path of this complex path-
way are present in a substantial percentage of cancers and 
other disorders.  This complexity can be demonstrated 
with an example involving EGFR.  EGFR is involved in the 
upstream and downstream regulation of the MAPK path-
way.  EGFR functions upstream by signaling the Ras protein 
in which case an EGFR mutation or over expression can 
cause hyperactivation of the MAPK pathway.  Additionally, 
one of the products of ERK signaling is TGF-α and other 
EGFR ligands whose over expression can lead to hyperacti-
vation of the pathway as well.  In order to combat the nu-
merous mutations which present themselves throughout 
this pathway, intense study and research is currently de-
voted to the development of Raf inhibitors, MEK inhibitors, 
Ras inhibitors, and EGFR inhibitors- our area of interest 
(Roberts, Der, 2007). 
EGFR Inhibitors 
 As a result of the large proportion of EGFR muta-
tions among Non Small Cell Lung Cancer, much effort has 
been devoted to the research and development of inhibi-
tor drugs which combat the neoplasia resulting from the 
over-expression of the EGFR proteins.  Novel target thera-
pies in the midst of development can aim at the specific 
EGFR oncogene as opposed to affecting all the cells in the 
body with chemotherapy, which has proven itself relatively 
ineffective in treatment of lung cancer (Vealel, et. al. 
1987).  Various research groups are exploring distinct 
methods of inhibiting the hyperactivity of the EGFR path-
way.  This inhibition is relatively harmless because the 
EGFR pathway does not play an essential role in the bodies 
of healthy adults, its inhibition causing a rash or diarrhea at 
most (Fukuoka, et. al. 2003).  Aside for the EGFR signal 
transduction pathway inhibitors discussed earlier, there 
are two forms of inhibitors of the EGF receptor itself cur-
rently in the form of marketable drugs.  These two forms 
of inhibitors are monoclonal antibodies and tyrosine kinase 
inhibitors.  Researchers are currently attempting to find 
the optimal combination of these two target therapies to-
gether with standard radiation and chemotherapy for each 
case of Lung Cancer.  Monoclonal antibodies, such as Ce-
Suzanne Freidman 
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tuximab, are large molecules that act from outside of the 
cell.  These antibodies inhibit EGFR activation by binding 
close enough to the ligand-binding site that it can block the 
ligand from binding to the receptor (Friday, Adjei, 2008).   
 Our inhibition drugs of interest are Tyrosine Kinase 
Inhibitors.  Tyrosine kinase inhibitors are small molecules 
with the ability to move through the cell membrane in or-
der to interact with the cytoplasmic EGFR do-
main.  Tyrosine kinase inhibitors exhibit competitive inhibi-
tion, binding to the tyrosine residues of the EGF receptor, 
thereby blocking ATP from binding and activating the EGFR 
and its downstream effectors.  This inhibition of the EGFR 
pathway has demonstrated clinical response and has pro-
longed life expectancy of EGFR mutation patients.  It is be-
lieved that the tyrosine kinase inhibitors discontinue the 
translation of EGFR effectors which had induced cellular 
proliferation and metastasis, thereby reducing the exces-
sive cell growth present in the malignancy (Massutí, 
2003).  Furthermore, it was proposed that tyrosine kinase 
inhibition induces apoptotic cell death by upregulation of 
Bim, a pro-apoptotic protein.  Another strong possibility is 
that tyrosine kinase inhibitors induce cell death by inhib-
iting mTOR, an autophagy-inhibitor protein whose activity 
is normally increased by EGFR activity.  Autophagy is the 
process of which the cellular organelles are swallowed up 
by lysosomal vesicles, but this process is normally regulat-
ed by the EGFR pathway.  With the EGFR pathways halted, 
this inhibition is weakened and autophagy becomes more 
prevalent amongst the malignant cells causing the desired 
cell death (Markus, Alain, 2013). 
 Two TKI drugs currently on the market are Ge-
fitinib/Iressa and Erlotinib/Tarceva.  In the randomized, 
double blind, Phase II trial of Gefitinib, the results were 
promising.  Included in the study were 210 advanced 
NSCLC patients who had been treated with chemotherapy 
once or twice and had received platinum treatment.  They 
were chosen to receive a daily oral dose of either 250-mg 
or 500-mg Gefitinib.  Tumor response rates were approxi-
mately 19% and the symptom improvement rate of evalua-
ble patients was approximately 40%.  Adverse effects were 
minimal in both cases consisting main of diarrhea and skin 
rashes (Fukuoka, et. al. 2003). 
 The Erlotinib results seem optimistic as well.  The 
international phase III Erlotinib trial was randomized, dou-
ble blind, and placebo controlled with a 2:1 ratio of 150mg 
daily dose of Erlotinib to the placebo group.  The placebo 
was considered ethical because further chemotherapy 
would not have benefitted these patients whose first or 
second bout of chemotherapy had failed.  Response rate 
was around 9% in the group who received Erlotinib and 
less than 1% in the placebo group.  Median survival was 
prolonged by two months (Shepherd, et. al. 2005). 
EGFR Mutations 
 The control that EGFR contains over cell prolifera-
tion and metastasis makes it a key protein for oncogenic 
mutation.  Hyperactivity of the EGFR pathway in any step 
of its complex network can lead to neoplasia.  This can 
happen through mutation, over expression, or amplifica-
tion of EGFR, its ligands, or a protein involved in the EGFR 
pathway.   
In a study done in Japan (Kosaka, et. al. 2004), tumor sam-
ples were obtained from 277 randomly selected patients 
(Figure 3).  Exons 18-21, the first four exons that code for 
the Tyrosine Kinase domain, were amplified and under-
went molecular analysis, as these areas had been previous-
ly shown to contain the EGFR mutations in conducted stud-
ies.  Mutations in this area of the tumor’s EGFR gene were 
found in 111 patients (40%).  There were 52 in-frame dele-
tion mutations, 54 point mutations, and 5 duplication/
insertion mutations.  The deletions were all around the five 
amino acids ELREA from codons 746-750 of exon 
19.  Approximately half were simple deletions and half 
were deletions coupled with point mutations or inser-
tions.   A Thymine to Guanine exchange at the second nu-
cleotide of codon 858 in exon 21 was found in 85% of the 
point mutations, leading to an exchange of Leucine for Ar-
ginine.  In summary, 91% of the EGFR mutations occurred 
as deletions around E746-A750 or as L858R point muta-
tions.  These two forms of mutations have come up in nu-
merous studies conducted in this area, proving to be 
strongly correlated with EGFR mutational Non-Small Cell 
Lung Cancer (NSCLC). 
Clinical Features Correlated to EGFR Aberration 
 As numerous studies were conducted, specific 
patterns of clinical and pathological features were found to 
Biomarkers in NSCLC Epidermal Growth Factor Receptor Mutations  
80 
 
cysteine residues in β-sheet formation and are highly regu-
lated by numerous signal transduction pathways through-
out the cell (Yarden, Sliwkowski, 2001).  TGF-α is the most 
common ligand (Vealel, et. al. 1987).  Following EGFR bind-
ing, dimerization of EGFR occurs to form a homodimer 
with an identical receptor or to form a heterodimer with a 
different protein of the ErbB family (Isobe et. al. 
2005).  Heterodimers are stronger than homodimers with 
a smaller rate of ligand dissociation, increased period of tie 
at the cell surface, and increased mitogenic capabili-
ties.  Dimerization leads to autophosphorylation of Tyro-
sine residues of the cytoplasmic region of the protein it-
self.  The specific regions activated on the Kinase domain, 
and consequently the specific pathways activated, are de-
pendent on the ligand’s identity as well as EGFR’s dimeriza-
tion partner.  EGFR’s activation allows it to bind to cyto-
plasmic messenger proteins which initiate various signal 
transduction cascades resulting in cell proliferation, metas-
tasis, and apoptosis aversion (Yarden, Sliwkowski, 2001). 
Raf-MEK-ERK Mitogen-Activated Protein Kinase  
Cascade 
 The most common EGFR signal transduction path-
way is the Raf-MEK-ERK Mitogen-Activated Protein Kinase 
Cascade (Figure 2).  This cascade contains a set of its own 
mutations throughout the steps of the pathway which are 
leading causes of cancer as well.  Mammalian cascades 
involving Mitogen-Activated Protein Kinases (MAPK’s) are 
part of a three step signaling process.  The MAPK Kinase 
Kinase (MAPKKK) signals the MAP Kinase (MAPKK) which 
then signals the MAPK (Roberts, Der, 2007).  In the EGFR 
MAPK cascade, active EGFR stimulates Raf, the MAPKKK, 
through association with adaptor protein Grb2 which re-
cruits SOS-1 nucleotide exchange factors to the cell mem-
brane.  SOS-1 activates Ras proteins by exchanging the 
GDP bound to Ras for GTP.  The activated Ras recruits Raf 
to the cell membrane and activates it through a complex 
process involving phosphorylation (Friday, Adjei, 
2008).  The Raf MAPKKK phosphorylates and activates MEK 
1 and 2, the MAPKK’s, which phosphorylate the MAPK’s- 
Extracellular signal-regulated kinases (ERK 1 and 
2).  Activated ERK’s go on to regulate numerous proteins 
and transcription factors, resulting in cell proliferation and 
survival.  Although this pathway has previously been con-
sidered linear, in reality it involves many complex interac-
tions with other pathways which regulate the different 
steps, mainly Raf Activation.  Studies have shown that mu-
tations in each step along the path of this complex path-
way are present in a substantial percentage of cancers and 
other disorders.  This complexity can be demonstrated 
with an example involving EGFR.  EGFR is involved in the 
upstream and downstream regulation of the MAPK path-
way.  EGFR functions upstream by signaling the Ras protein 
in which case an EGFR mutation or over expression can 
cause hyperactivation of the MAPK pathway.  Additionally, 
one of the products of ERK signaling is TGF-α and other 
EGFR ligands whose over expression can lead to hyperacti-
vation of the pathway as well.  In order to combat the nu-
merous mutations which present themselves throughout 
this pathway, intense study and research is currently de-
voted to the development of Raf inhibitors, MEK inhibitors, 
Ras inhibitors, and EGFR inhibitors- our area of interest 
(Roberts, Der, 2007). 
EGFR Inhibitors 
 As a result of the large proportion of EGFR muta-
tions among Non Small Cell Lung Cancer, much effort has 
been devoted to the research and development of inhibi-
tor drugs which combat the neoplasia resulting from the 
over-expression of the EGFR proteins.  Novel target thera-
pies in the midst of development can aim at the specific 
EGFR oncogene as opposed to affecting all the cells in the 
body with chemotherapy, which has proven itself relatively 
ineffective in treatment of lung cancer (Vealel, et. al. 
1987).  Various research groups are exploring distinct 
methods of inhibiting the hyperactivity of the EGFR path-
way.  This inhibition is relatively harmless because the 
EGFR pathway does not play an essential role in the bodies 
of healthy adults, its inhibition causing a rash or diarrhea at 
most (Fukuoka, et. al. 2003).  Aside for the EGFR signal 
transduction pathway inhibitors discussed earlier, there 
are two forms of inhibitors of the EGF receptor itself cur-
rently in the form of marketable drugs.  These two forms 
of inhibitors are monoclonal antibodies and tyrosine kinase 
inhibitors.  Researchers are currently attempting to find 
the optimal combination of these two target therapies to-
gether with standard radiation and chemotherapy for each 
case of Lung Cancer.  Monoclonal antibodies, such as Ce-
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tuximab, are large molecules that act from outside of the 
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Inhibitors.  Tyrosine kinase inhibitors are small molecules 
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thereby blocking ATP from binding and activating the EGFR 
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pathway has demonstrated clinical response and has pro-
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were chosen to receive a daily oral dose of either 250-mg 
or 500-mg Gefitinib.  Tumor response rates were approxi-
mately 19% and the symptom improvement rate of evalua-
ble patients was approximately 40%.  Adverse effects were 
minimal in both cases consisting main of diarrhea and skin 
rashes (Fukuoka, et. al. 2003). 
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was considered ethical because further chemotherapy 
would not have benefitted these patients whose first or 
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was around 9% in the group who received Erlotinib and 
less than 1% in the placebo group.  Median survival was 
prolonged by two months (Shepherd, et. al. 2005). 
EGFR Mutations 
 The control that EGFR contains over cell prolifera-
tion and metastasis makes it a key protein for oncogenic 
mutation.  Hyperactivity of the EGFR pathway in any step 
of its complex network can lead to neoplasia.  This can 
happen through mutation, over expression, or amplifica-
tion of EGFR, its ligands, or a protein involved in the EGFR 
pathway.   
In a study done in Japan (Kosaka, et. al. 2004), tumor sam-
ples were obtained from 277 randomly selected patients 
(Figure 3).  Exons 18-21, the first four exons that code for 
the Tyrosine Kinase domain, were amplified and under-
went molecular analysis, as these areas had been previous-
ly shown to contain the EGFR mutations in conducted stud-
ies.  Mutations in this area of the tumor’s EGFR gene were 
found in 111 patients (40%).  There were 52 in-frame dele-
tion mutations, 54 point mutations, and 5 duplication/
insertion mutations.  The deletions were all around the five 
amino acids ELREA from codons 746-750 of exon 
19.  Approximately half were simple deletions and half 
were deletions coupled with point mutations or inser-
tions.   A Thymine to Guanine exchange at the second nu-
cleotide of codon 858 in exon 21 was found in 85% of the 
point mutations, leading to an exchange of Leucine for Ar-
ginine.  In summary, 91% of the EGFR mutations occurred 
as deletions around E746-A750 or as L858R point muta-
tions.  These two forms of mutations have come up in nu-
merous studies conducted in this area, proving to be 
strongly correlated with EGFR mutational Non-Small Cell 
Lung Cancer (NSCLC). 
Clinical Features Correlated to EGFR Aberration 
 As numerous studies were conducted, specific 
patterns of clinical and pathological features were found to 
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be present in the lung cancer patients involved in the stud-
ies.  Female gender, non-smoking history, Asian descent, 
and Adenocarcinoma were all found to be directly related 
to EGFR mutations in NSCLC.  EGFR mutations are almost 
completely exclusive to adenocarcinomas in all conducted 
studies.  In the Japanese study, only one out of 111 EGFR 
mutated patients had nonadenocarcinoma.  In a similar 
study conducted in Italy (Marchetti, et. al.2005), EGFR mu-
tations were found exclusively in the adenocarcinoma pa-
tients.  Smoking history showed significantly high statistical 
correlation to EGFR mutations as well.  Fifty nine percent 
of the patients in the Italian study with mutated EGFR pro-
teins were nonsmokers and 41% were smokers or former 
smokers.  The study in Japan takes this smoking correlation 
a step further after completing more advanced statistical 
analysis solely on the Adenocarcinoma patients.   They di-
vided the smokers into three categories depending on the 
length of the period of time spent smoking, and it was dis-
covered that the higher the exposure to smoking, the low-
er the percentage of EGFR mutation was found in that sub-
group of patients, refuting the hypothesis that smoking is 
related to NSCLC. 
 In terms of gender, in both the Japanese and Ital-
ian studies as well as numerous other studies conducted 
on this subject, the females were a significantly larger per-
centage of the NSCLC patients found with the EGFR muta-
tion.  However, because female patients are usually non-
smokers as well as Adenocarcinoma type cancer patients, 
the Japanese study performed logistic regression analysis 
to determine if gender contributed independently to EGFR 
mutation.  The result demonstrated that only Adenocarci-
noma histology and smoking status contributed inde-
pendently to EGFR mutation, while female gender was an 
outcome of the other features that were present amongst 
females in a higher percentage than males.  Similar results 
were found in many other studies as well.  Furthermore, 
an added observation was made on the small number of 
patients under the age of 50, menopause age in Japan.  It 
was found that the EGFR mutation in these younger pa-
tients did not lean toward the female gender, further dis-
counting theories of hormonal activity affecting the EGFR 
protein in females. 
 Japanese NSCLC patients were confirmed numer-
ous times for having a higher proportion of EGFR mutation 
than American NSCLC patients (Kosaka, et. al. 
2004).  However, this feature is likely a result of other com-
monly found features in Asian populations.  There are a 
significantly lower percentage of NSCLC patients with a 
history of smoking in Japan than in America.  In the Japa-
nese study, 83% of the female and 10% of the male pa-
tients were non-smokers, which is typical of Japanese pa-
tients.  The conductors of this study note that in a parallel 
American study, however, 15% of the female and 6% of 
the male patients were never-smokers.  These results were 
characteristic of many studies which evaluated American 
versus Asian smoking history. 
Discussion 
There has been great success in the area of EGFR target 
therapy, as well as with target therapy in general as a cure 
for cancer.  However, in order to continue in the path to-
ward success, clearer biomarkers must be established 
which can help to narrow down the population to which 
the drug is originally administered.  Currently, the percent-
age of response to EGFR TKI’s is only around 10% 
(Fukuoka, et. al. 2003, Shepherd,et. al.  2005).  The current 
goal of the ongoing research in this area is to hone in on 
this 10% of patients, using research and experimentation 
to solve the mystery of their success.  Eventually, as the 
response to each target therapy is clearly understood, 
each patient will be given his or her optimal drug combina-
tion, and greater response rates will be seen with cancer 
patients worldwide. 
 An integral step toward this goal is the determina-
tion of objective patient features for each target therapy 
which will signal success (or failure) in the inhibition of the 
gene of interest.  A standard, quantitative scoring system 
for assessment must be established to determine if the 
target therapy is, in actuality, blocking what it was intend-
ed to block and if that blockage elicits a positive clinical 
response.  New technology is being developed to assist the 
research in this area such as cDNA Arrays which will allow 
the identification of genes regulated by anti-EGFR thera-
pies.   Protein Arrays could be used to explore the proteins 
involved in the EGFR pathways (Baselga, Arteaga, 2005). 
 Once clear signs of drug success have been estab-
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lished, it is necessary to explore the correlation between 
clinical-pathological patient biomarkers and drug success 
(or failure).  Research is being conducted to explore the 
patterns of clinical patient features which are more preva-
lent among patients who responded to the drug.  The two 
forms of biomarkers being researched amongst NSCLC pa-
tients are genetics and clinical characteristics.  The genetic 
sequence mutations amongst EGFR NSCLC patients are 
somewhat clear.  The two main mutations are the E746-
A750 deletion as well as the L858R point mutation. Howev-
er, the clinical patient features commonly prevalent in 
EGFR mutation patients must be examined further.  In or-
der to accomplish this goal, there are those who believe 
that a “No tissue-No trial” rule should be enacted in which 
a patient whose molecules of interest are unclear in the 
tissue would be excluded from the trial.  This way, only 
patients who will help research further its goal of establish-
ing a connection between drug response and biomarkers 
would be granted the drug (Baselga, Arteaga, 2005). 
 In terms of clinical features, it seems that the two 
characteristics which independently correlate to EGFR mu-
tation are adenocarcinoma type cancer and non-smoking 
history.  Female gender prevalence in drug response is a 
likely outcome of its correlation to Adenocarcinoma and 
non-smoking history.   The results of the logistic regression 
analysis in many studies and trials did not point to female 
gender with an independent correlation to drug re-
sponse.  Additionally, the analysis of the pre-menopause 
patients in the Japanese study points to the same conclu-
sion; female gender does not independently correlate with 
EGFR inhibition response rate.  In the Gefitinib trial, no 
pharmacokinetic differences were found between men and 
women (Fukuoka, et. al. 2003). 
 The prevalence of drug response in Asian popula-
tions does not hold its own when scrutinized with more 
complex methods of statistical analysis.  Upon observing a 
higher response rate for Japanese patients in the Gefitinib 
trial, a pharmacokinetic analysis was conducted which did 
not reveal any differences between Japanese and non-
Japanese patients.  Additionally, after an extremely com-
plex logistic analysis with multiple variables involved, Asian 
descent response rates were not considered statistically 
significant (Fukuoka, et. al. 2003). 
 However, the connection between EGFR mutation 
and the independent characteristics of adenocarcinoma 
and smoking history are pretty firmly established.  Fukuoka 
(2003) postulates that the slow growth of adenocarcino-
mas may lend itself to successful drug response.   
Conclusion 
 The true link between prevalent clinical traits and 
drug response rate can only be understood with a deeper 
understanding of the complex EGFR network of signal 
transduction pathways and cross talk found amongst them. 
This will be possible with the use of technology such as 
genetic and protein arrays as well as analysis of future 
studies.  This understanding, coupled with the knowledge 
of clear biomarkers, will allow for target drug administra-
tion to specific populations and higher response rates in 
EGFR inhibitor drugs.  Target cancer drugs will eventually 
be administered to the small percentage of the population 
who will likely respond to the drug, thereby efficiently cre-
ating a higher success rate of target therapy. 
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be present in the lung cancer patients involved in the stud-
ies.  Female gender, non-smoking history, Asian descent, 
and Adenocarcinoma were all found to be directly related 
to EGFR mutations in NSCLC.  EGFR mutations are almost 
completely exclusive to adenocarcinomas in all conducted 
studies.  In the Japanese study, only one out of 111 EGFR 
mutated patients had nonadenocarcinoma.  In a similar 
study conducted in Italy (Marchetti, et. al.2005), EGFR mu-
tations were found exclusively in the adenocarcinoma pa-
tients.  Smoking history showed significantly high statistical 
correlation to EGFR mutations as well.  Fifty nine percent 
of the patients in the Italian study with mutated EGFR pro-
teins were nonsmokers and 41% were smokers or former 
smokers.  The study in Japan takes this smoking correlation 
a step further after completing more advanced statistical 
analysis solely on the Adenocarcinoma patients.   They di-
vided the smokers into three categories depending on the 
length of the period of time spent smoking, and it was dis-
covered that the higher the exposure to smoking, the low-
er the percentage of EGFR mutation was found in that sub-
group of patients, refuting the hypothesis that smoking is 
related to NSCLC. 
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